Since 2012, we have delivered well over 200 humanization projects. This Insights piece discusses how we use our proprietary CDRx™ humanization platform which not only guarantees affinity to within 2x that of the parental antibody, including more difficult molecules from rabbit origin, but we often observe several-fold affinity improvements.
With a quality by design approach, we employ our in silico and protein engineering expertise to design and optimize an engineering program ideal for an antibody candidate, shaped with the endpoint in mind.
World-renowned experts in the fields of antibody engineering Matthew Baker Ph.D., Professor Terry Rabbitts, and Professor Charlotte Deane to join Fusion Antibodies Scientific Advisory Panel
Fusion Antibodies has decided to include Omicron RBD, alongside the alpha, beta, gamma and delta+ RBD variants, in its development programme with the aim of producing virus-neutralising antibodies.
An interview with our CEO, Dr Richard Jones talking about our significant contract announcement with a US BioTech.
New $1.83 million R&D project win for Fusion Antibodies reinforces its position as one of the leading providers of early-stage antibody discovery and engineering services.
